Yonsei University · Medicine
Professor Daehoon Kim's research lab focuses on cardiovascular and cerebrovascular diseases, with a strong emphasis on atrial fibrillation (AF) and its long-term complications, including dementia and cognitive decline. The lab investigates the impact of rhythm and rate control strategies, anticoagulant adherence, and comorbid conditions such as hypertension on clinical outcomes in AF patients. Using large-scale national databases, the lab explores mechanisms linking AF to neurocognitive impairment and identifies modifiable risk factors, particularly in midlife populations. The research also extends into molecular mechanisms of epigenetic regulators like CARM1, linking cellular signaling to disease pathogenesis.
Figures are computed from collected data and may differ slightly.
Early initiation of rhythm control treatment was associated with a lower risk of adverse cardiovascular outcomes than rate control treatment in patients with recently diagnosed atrial fibrillation. This association was not found in patients who had had atrial fibrillation for more than one year.
AF hospitalisations have increased exponentially over the past 10 years in Korea, in association with an increase in comorbid chronic diseases. Mortality associated with AF hospitalisations decreased during the last decade, but hospitalisation costs have markedly increased.
In this nationwide cohort of AF patients treated with catheter ablation or medical therapy, ablation was associated with decreased dementia risk. This relationship was evident after censoring for stroke and adjusting for clinical confounders.
CARM1 is one of nine protein arginine methyltransferases that methylate arginine residues in proteins. CARM1 is recruited by many different transcription factors as a positive regulator. Gene targeting of CARM1 in mice has been performed, and knock-out mice, which are smaller than their wild-type littermates, die just after birth. It has been proposed that CARM1 has functions that are independent of its enzymatic activity. Indeed, CARM1 is found to interact with a number of proteins and may have
In an adherence level-dependent fashion, adherent use of NOAC showed better clinical outcomes without increasing bleeding risk. Maintaining ≥90% of adherence optimizes effectiveness of NOAC therapy without compromising its safety.
Atrial fibrillation (AF) is associated with increased risk of cognitive impairment and dementia, even with no overt stroke. Hypertension has been a potentially modifiable risk factor for dementia, especially in midlife (<70 years) individuals. We aimed to investigate the associations of blood pressure (BP) and hypertension burden with dementia risk among midlife AF patients. From the Korean National Health Insurance Service database, we enrolled 171 228 incident AF patients aged 50 to 69 years w
In this propensity-matched and -weighted analysis using a real-world population-based cohort, use of NOACs was associated with lower dementia risk than use of warfarin among non-valvular AF patients initiating OAC treatment.
ClinicalTrials.gov Identifier: NCT04432220.
Open papers in the app to read, cite, and organize with AI.
